Débridat

Débridat

Trimebutine

motor disorders in functional diseases of the gastrointestinal tract,

gastroesophageal reflux disease,

dyspeptic disorders in gastroduodenal diseases (abdominal pain, digestive disorders, nausea, vomiting),

irritable bowel syndrome (a functional disease of the gastrointestinal tract, manifested, in particular, by pain and colic in the abdominal cavity, intestinal spasms, flatulence, diarrhea and / or constipation),

postoperative paralytic intestinal obstruction,

preparation for X-ray and endoscopic examinations of the gastrointestinal tract,

dyspeptic disorders associated with impaired gastrointestinal motility in children.

Inside.

Adults and children from 12 years old - 100-200 mg 3 times a day. To prevent the recurrence of irritable bowel syndrome after the course of treatment during remission, it is recommended to continue taking the drug at a dose of 300 mg/day for 12 weeks.

Children 3-5 years old - 25 mg 3 times a day, 5-12 years old - 50 mg 3 times a day.

hypersensitivity to the components included in the composition of the drug,

children under 3 years of age.

Rarely-skin reactions.

To date, cases of overdose of the drug Débridat have been reported^® was not reported.

• Antispasmodic agent [Other gastrointestinal agents]

Drug interaction of the drug Débridat^® not described.

Trimebutin, acting on the enkephalinergic system of the intestine, is a regulator of its peristalsis. Having an affinity for the receptors of excitation and suppression, it has a stimulating effect in hypokinetic conditions of the smooth muscles of the intestine and an antispasmodic effect in hyperkinetic conditions. The drug acts throughout the gastrointestinal tract, reduces the pressure of the esophageal sphincter, promotes gastric emptying and increases intestinal peristalsis, as well as the development of a response of the smooth muscles of the colon to food stimuli.

Trimebutin restores the normal physiological activity of the intestinal muscles in various diseases of the gastrointestinal tract associated with motor disorders.

After oral administration, trimebutin is rapidly absorbed from the gastrointestinal tract. T_max in blood plasma-1-2 hours. Bioavailability is 4-6%. V_d - 88 l.

The degree of binding to plasma proteins is low — about 5%. Trimebutin slightly penetrates the placental barrier.

Metabolism and excretion. Trimebutin is biotransformed in the liver and excreted in the urine mainly as metabolites (approximately 70% during the first 24 hours). T_1/2 - about 12 hours.